457 related articles for article (PubMed ID: 19415126)
21. Stepping closer to treating Alzheimer's disease patients with BACE1 inhibitor drugs.
Yan R
Transl Neurodegener; 2016; 5():13. PubMed ID: 27418961
[TBL] [Abstract][Full Text] [Related]
22. Energy inhibition elevates beta-secretase levels and activity and is potentially amyloidogenic in APP transgenic mice: possible early events in Alzheimer's disease pathogenesis.
Velliquette RA; O'Connor T; Vassar R
J Neurosci; 2005 Nov; 25(47):10874-83. PubMed ID: 16306400
[TBL] [Abstract][Full Text] [Related]
23. Increased NF-κB signalling up-regulates BACE1 expression and its therapeutic potential in Alzheimer's disease.
Chen CH; Zhou W; Liu S; Deng Y; Cai F; Tone M; Tone Y; Tong Y; Song W
Int J Neuropsychopharmacol; 2012 Feb; 15(1):77-90. PubMed ID: 21329555
[TBL] [Abstract][Full Text] [Related]
24. The β-secretase enzyme BACE1 as a therapeutic target for Alzheimer's disease.
Vassar R; Kandalepas PC
Alzheimers Res Ther; 2011 May; 3(3):20. PubMed ID: 21639952
[TBL] [Abstract][Full Text] [Related]
25. Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models.
Natunen T; Takalo M; Kemppainen S; Leskelä S; Marttinen M; Kurkinen KMA; Pursiheimo JP; Sarajärvi T; Viswanathan J; Gabbouj S; Solje E; Tahvanainen E; Pirttimäki T; Kurki M; Paananen J; Rauramaa T; Miettinen P; Mäkinen P; Leinonen V; Soininen H; Airenne K; Tanzi RE; Tanila H; Haapasalo A; Hiltunen M
Neurobiol Dis; 2016 Jan; 85():187-205. PubMed ID: 26563932
[TBL] [Abstract][Full Text] [Related]
26. Highlights in BACE1 Inhibitors for Alzheimer's Disease Treatment.
Coimbra JRM; Marques DFF; Baptista SJ; Pereira CMF; Moreira PI; Dinis TCP; Santos AE; Salvador JAR
Front Chem; 2018; 6():178. PubMed ID: 29881722
[TBL] [Abstract][Full Text] [Related]
27. BACE1 elevation engendered by GGA3 deletion increases β-amyloid pathology in association with APP elevation and decreased CHL1 processing in 5XFAD mice.
Kim W; Ma L; Lomoio S; Willen R; Lombardo S; Dong J; Haydon PG; Tesco G
Mol Neurodegener; 2018 Feb; 13(1):6. PubMed ID: 29391027
[TBL] [Abstract][Full Text] [Related]
28. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription.
Li Y; Zhou W; Tong Y; He G; Song W
FASEB J; 2006 Feb; 20(2):285-92. PubMed ID: 16449801
[TBL] [Abstract][Full Text] [Related]
29. P-glycoprotein efflux and other factors limit brain amyloid beta reduction by beta-site amyloid precursor protein-cleaving enzyme 1 inhibitors in mice.
Meredith JE; Thompson LA; Toyn JH; Marcin L; Barten DM; Marcinkeviciene J; Kopcho L; Kim Y; Lin A; Guss V; Burton C; Iben L; Polson C; Cantone J; Ford M; Drexler D; Fiedler T; Lentz KA; Grace JE; Kolb J; Corsa J; Pierdomenico M; Jones K; Olson RE; Macor JE; Albright CF
J Pharmacol Exp Ther; 2008 Aug; 326(2):502-13. PubMed ID: 18499745
[TBL] [Abstract][Full Text] [Related]
30. Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons.
Mamada N; Tanokashira D; Hosaka A; Kametani F; Tamaoka A; Araki W
Mol Brain; 2015 Nov; 8(1):73. PubMed ID: 26552445
[TBL] [Abstract][Full Text] [Related]
31. BACE1 inhibitors: Current status and future directions in treating Alzheimer's disease.
Moussa-Pacha NM; Abdin SM; Omar HA; Alniss H; Al-Tel TH
Med Res Rev; 2020 Jan; 40(1):339-384. PubMed ID: 31347728
[TBL] [Abstract][Full Text] [Related]
32. Function, regulation and therapeutic properties of beta-secretase (BACE1).
Willem M; Lammich S; Haass C
Semin Cell Dev Biol; 2009 Apr; 20(2):175-82. PubMed ID: 19429494
[TBL] [Abstract][Full Text] [Related]
33. Control of BACE1 degradation and APP processing by ubiquitin carboxyl-terminal hydrolase L1.
Zhang M; Deng Y; Luo Y; Zhang S; Zou H; Cai F; Wada K; Song W
J Neurochem; 2012 Mar; 120(6):1129-38. PubMed ID: 22212137
[TBL] [Abstract][Full Text] [Related]
34. Distinct transcriptional regulation and function of the human BACE2 and BACE1 genes.
Sun X; Wang Y; Qing H; Christensen MA; Liu Y; Zhou W; Tong Y; Xiao C; Huang Y; Zhang S; Liu X; Song W
FASEB J; 2005 May; 19(7):739-49. PubMed ID: 15857888
[TBL] [Abstract][Full Text] [Related]
35. Reduction of the expression of the late-onset Alzheimer's disease (AD) risk-factor
Andrew RJ; De Rossi P; Nguyen P; Kowalski HR; Recupero AJ; Guerbette T; Krause SV; Rice RC; Laury-Kleintop L; Wagner SL; Thinakaran G
J Biol Chem; 2019 Mar; 294(12):4477-4487. PubMed ID: 30692199
[TBL] [Abstract][Full Text] [Related]
36. An aberrant sugar modification of BACE1 blocks its lysosomal targeting in Alzheimer's disease.
Kizuka Y; Kitazume S; Fujinawa R; Saito T; Iwata N; Saido TC; Nakano M; Yamaguchi Y; Hashimoto Y; Staufenbiel M; Hatsuta H; Murayama S; Manya H; Endo T; Taniguchi N
EMBO Mol Med; 2015 Feb; 7(2):175-89. PubMed ID: 25592972
[TBL] [Abstract][Full Text] [Related]
37. The β-Secretase Enzyme BACE1: A Biochemical Enigma for Alzheimer's Disease.
Shah H; Patel A; Parikh V; Nagani A; Bhimani B; Shah U; Bambharoliya T
CNS Neurol Disord Drug Targets; 2020; 19(3):184-194. PubMed ID: 32452328
[TBL] [Abstract][Full Text] [Related]
38. Alternative Selection of β-Site APP-Cleaving Enzyme 1 (BACE1) Cleavage Sites in Amyloid β-Protein Precursor (APP) Harboring Protective and Pathogenic Mutations within the Aβ Sequence.
Kimura A; Hata S; Suzuki T
J Biol Chem; 2016 Nov; 291(46):24041-24053. PubMed ID: 27687728
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of intracellular trafficking and endosomal sorting in Alzheimer's disease: controversies and unanswered questions.
Toh WH; Gleeson PA
Biochem J; 2016 Jul; 473(14):1977-93. PubMed ID: 27407168
[TBL] [Abstract][Full Text] [Related]
40. Decrease in brain soluble amyloid precursor protein β (sAPPβ) in Alzheimer's disease cortex.
Wu G; Sankaranarayanan S; Hsieh SH; Simon AJ; Savage MJ
J Neurosci Res; 2011 Jun; 89(6):822-32. PubMed ID: 21433051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]